Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

rasagiline mesylate

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
IMPORTANCE Preladenant is an adenosine 2A receptor antagonist that reduced "off" time in a placebo-controlled phase 2b trial in… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
The main goal of the present study was to evaluate applicability of the different model substrates, namely orodispersible films… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2009
2009
In the present study, a reverse phase high performance liquid chromatographic method was developed and validated for the… Expand
  • figure 1
  • figure 2
  • table 2
  • table 4
  • table 5
Is this relevant?
2008
2008
Rasagiline is a novel selective irreversible monoamine oxidase-B (MAO-B) inhibitor recently introduced for the symptomatic… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2008
2008
Monoamine oxidase inhibitors are associated with dietary tyramine interactions that can induce hypertensive crises. Rasagiline… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND Rasagiline mesylate is a novel drug for Parkinson's disease with selective, irreversible monoamine oxidase B (MAO-B… Expand
Is this relevant?
Highly Cited
2004
Highly Cited
2004
BACKGROUND Treatment with rasagiline mesylate, an irreversible monoamine oxidase type B inhibitor, improves symptoms of early… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2002
Highly Cited
2002
CONTEXT Monotherapy with rasagiline mesylate may be useful in early Parkinson disease (PD). OBJECTIVE To evaluate the safety… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2000
Highly Cited
2000
Rasagiline mesylate (TVP-1012) is a potent, selective, non-reversible MAO-B inhibitor, without the tyramine-potentiating effect… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
1998
1998
Rasagiline (N-propargyl-1(R)aminoindan) is a selective and potent MAO-B inhibitor currently under development as the mesylate… Expand
Is this relevant?